Trials / Completed
CompletedNCT03895203
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 852 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Subjects will receive bimekizumab at pre-specified time-points. |
| DRUG | Adalimumab | Adalimumab will be administered according to the labeling recommendations. |
| OTHER | Placebo | Subjects will receive placebo at pre-specified time-points. |
Timeline
- Start date
- 2019-04-03
- Primary completion
- 2021-08-17
- Completion
- 2022-07-11
- First posted
- 2019-03-29
- Last updated
- 2026-01-27
- Results posted
- 2024-10-23
Locations
136 sites across 14 countries: United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03895203. Inclusion in this directory is not an endorsement.